Meitav Investment House Ltd. Lowers Holdings in Urogen Pharma $URGN

Meitav Investment House Ltd. reduced its position in shares of Urogen Pharma (NASDAQ:URGN) by 37.4% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 22,223 shares of the company’s stock after selling 13,294 shares during the period. Meitav Investment House Ltd.’s holdings in Urogen Pharma were worth $400,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in URGN. SG Americas Securities LLC boosted its stake in Urogen Pharma by 20.3% during the first quarter. SG Americas Securities LLC now owns 1,657,846 shares of the company’s stock valued at $29,808,000 after buying an additional 280,199 shares during the period. Invesco Ltd. raised its holdings in shares of Urogen Pharma by 21.1% in the 4th quarter. Invesco Ltd. now owns 27,066 shares of the company’s stock valued at $634,000 after acquiring an additional 4,711 shares in the last quarter. Susquehanna Portfolio Strategies LLC purchased a new stake in shares of Urogen Pharma in the 4th quarter valued at about $641,000. Superstring Capital Management LP boosted its position in shares of Urogen Pharma by 717.1% during the 4th quarter. Superstring Capital Management LP now owns 718,354 shares of the company’s stock valued at $16,824,000 after acquiring an additional 630,442 shares during the last quarter. Finally, Orbimed Advisors LLC boosted its position in shares of Urogen Pharma by 27.1% during the 4th quarter. Orbimed Advisors LLC now owns 875,487 shares of the company’s stock valued at $20,504,000 after acquiring an additional 186,487 shares during the last quarter. Institutional investors own 91.29% of the company’s stock.

Insiders Place Their Bets

In other Urogen Pharma news, insider Mark Schoenberg sold 10,000 shares of the business’s stock in a transaction on Monday, June 22nd. The shares were sold at an average price of $35.01, for a total value of $350,100.00. Following the completion of the sale, the insider directly owned 129,763 shares of the company’s stock, valued at $4,543,002.63. The trade was a 7.15% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 4.80% of the stock is owned by corporate insiders.

Urogen Pharma Price Performance

Shares of URGN opened at $37.75 on Wednesday. Urogen Pharma has a 1 year low of $13.26 and a 1 year high of $39.58. The stock has a 50 day simple moving average of $30.37 and a two-hundred day simple moving average of $24.10. The firm has a market cap of $1.84 billion, a P/E ratio of -13.73 and a beta of 1.56.

Urogen Pharma (NASDAQ:URGN) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($0.47) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.48) by $0.01. The business had revenue of $50.96 million during the quarter, compared to the consensus estimate of $44.83 million. On average, equities analysts anticipate that Urogen Pharma will post -0.88 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on URGN. Jefferies Financial Group upgraded shares of Urogen Pharma to a “strong-buy” rating in a research report on Friday, April 24th. HC Wainwright reissued a “buy” rating and issued a $45.00 price target on shares of Urogen Pharma in a report on Wednesday, June 3rd. LADENBURG THALM/SH SH began coverage on shares of Urogen Pharma in a research report on Monday, May 11th. They set a “buy” rating and a $43.00 price objective on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Urogen Pharma in a report on Monday, April 20th. Finally, D. Boral Capital reiterated a “buy” rating and issued a $33.00 target price on shares of Urogen Pharma in a research report on Tuesday, March 31st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $39.50.

Urogen Pharma Company Profile

UroGen Pharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for uro-oncology and uro-genital diseases. Founded in 2010 and headquartered in Ra’anana, Israel, with offices in New York, UroGen applies its proprietary RTGel® reverse thermal gel delivery platform to create sustained-release formulations designed for in-office use by urologists.

The company’s lead product, Jelmyto® (mitomycin gel), received U.S. Food and Drug Administration approval in 2020 for the treatment of adults with low-grade upper tract urothelial cancer.